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Abstract The a suhunits of the leukocyte CDl l lCD18 integrins 
contain a ~200 amino acid 'inserted' or I domain. The I domain 
of the cell-surface Mac-1 (CD 11 b/CD18) integrin has been shown 
to be the major recognition site for several adhesion ligands, 
including iC3b, fibrinogen, factor X, and ICAM-1. The I domain 
from the Mac-1 a subunit has been expressed in Escherichia coli 
as a soluble GST-fusion protein containing a factor X" sensitive 
cleavage site. Analytical characterization of the purified I domain 
reveals that it is obtained in very high quality at high yields. CD 
and NMR spectra indicate that I domain adopts a predominantly 
folded structure in solution, independent of the remainder of the 
a subunit. Addition of Ca 2+ and Mg 2+ did not significantly perturb 
the structural conformation. 
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I. Introduction 
Cell adhesion molecules play a role in a wide variety of 
cellular processes, including development, metastasis, hemosta- 
sis, and inflammation [1]. Understanding how these molecules 
function at the molecular level in these processes may have 
therapeutic value [2]. Leukocyte integrins, or fl2-integrins con- 
stitute a subfamily of these adhesion molecules which are dis- 
tributed exclusively on the surface ofleukocytes. The leukocyte 
integrins, LFA-I (~ttfl2, CDl la /CD18) ,  Mac-1 (~zMfl2, CR3, 
CDl lb /CD18) ,  p150,95 (Ctxfl2, CDl lc /CD18)  and CDl ld /  
CDI8  are closely related cell surface receptors that mediate 
neutrophil attachment o the endothelium [3-6]. All four 
glycoproteins are ~fl heterodimers consisting of a common/3 
subunit (CD18, Mr 95,000) non-covalently associated with a 
unique but structurally homologous 0t subunit (CD l la ,  M~ 
175,000; CDl lb ,  M,. 160,000: CDl l c ,  Mr 155,000; CDI ld ,  M r 
150,000) [7 12]. At least 14 distinct ct and 8 distinct fl integrin 
subunits have been identified [4], but only the cz subunits of 
VLA-I (czlflt) [13], and VLA-2 (~z~l) [14], and the four leuko- 
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cyte integrins contain a domain of ca. 200 amino acids termed 
the I (inserted, interactive) domain [15,16]. The I domain shows 
sequence similarities to domains of von Willebrand factor, car- 
tilage matrix protein, and complement factor B [9,10,17]. 
Of the four known members of the fl~-integrins, Mac-1 has 
been shown to be a receptor for a variety of proteins associated 
with cell surfaces and the extracellular matrix. Several ines of 
evidence suggest hat the I domain plays an integral role in 
Mac-I function. Diamond et al. [18] showed that a number of 
monoclonal antibodies (mAbs) that block Mac-I dependent 
adhesion map to the I domain. At about the same time, Mic- 
hishita et al. [19] found that point mutations in tile I domain 
region of recombinant Mac-1 abolished binding to its iC3b 
ligand. A recombinant form of the I domain of Mac-I was 
shown to bind to functionally blocking mAbs, as well as to 
fibrinogen and soluble ICAM-1, other known ligands of Mac-1 
[20]. Finally, the I domain has been identified as the site on 
Mac-1 for binding of a hookworm-derived inhibitor of neutro- 
phil adhesion called NIF (21). 
Understanding the molecular basis for the 1 domain/ligand 
interactions is of critical importance to the design of small 
molecules that may alter these interactions. The present report 
describes the purification of unlabeled and ~5N-enriched I do- 
main from a glutathione S-transferase fusion construct ex- 
pressed in Escherichia coli, and its subsequent structural char- 
acterization by circular dichroism (CD) and NMR spectros- 
copy to show that it adopts a predominantly folded structure 
in solution. It should, theret\~re, be feasible to obtain structural 
insights regarding l domain recognition without the necessity 
to determine the structure of the entire 250 kDa c~fl hetero- 
dimer. 
2. Materials and methods 
2.1. Expression and pur(fication o/ GST/I domain jilsion proteins 
The Mac-1 c~ subunit is a transmembrane protein, with the I domain 
inserted toward the N-terminus of the protein. The 1 domain was 
recombinantly expressed in £ coli as a fusion protein to glutathione 
S-transferase (GST) as shown in Fig. 1. The pGEX-3X vector was used 
to construct a plasmid containing GST followed by a factor X ~' sensitive 
site and finally residues Ser ~33 Glu 3~r of CDI lb which correspond to 
the l domain [22]. Cells expressing the fusion protein were harvested 
from 3.0~4.5 liters of fermentation broth and lysed by sonication. The 
cell lysate was clarified by centrifugation at 40,000 x ~ followed by 
filtration through a 0.45 #m membrane. The filtrate was then loaded 
directly onto a glutathione Sepharose (Pharmacia) affinity column (50 
ml: 1.6 x 26 cm) pre-equilibrated with PBS/0.2%/Loctyl glucoside, pH 
7.4. The column was loaded at 1.0 ml/min and protein detection was 
monitored at 280 nm. The column was washed with 4 column volumes 
(CV) of equilibration buffer and step-eluted with 2 CV of 50 mM Tris 
buffer, pH 8.0, containing 20 mM reduced glutathione. Eluent fractions 
were subjected to 10 20% SDS-PAGE under non-reducing conditions. 
All rights reserved. 
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Fractions containing GST/I domain were pooled and stored at 4°C. 
The purity of the fusion protein thus obtained is approximately 95%, 
with the remainder of the protein appearing to be free-GST. Liberation 
of the I domain was achieved enzymatically by directly adding factor 
X" (Boehringer-Mannheim; sequencing grade) to a final concentration 
of 0.5% (by weight) and allowing the digestion to proceed for 1624 h 
at 23°C. I domain was then purified by directly loading the digestion 
mixture onto an S-Sepharose Fast Flow cation exchange column (50 
ml; 1.6 × 26 cm) pre-equilibrated with 50 mM sodium phosphate buffer, 
pH 6.5. The column was run at 1.0 ml/min and the effluent monitored 
at 280 nm (Fig. 2). The column was washed with 4 CV of equilibration 
buffer, followed by a linear gradient of increasing NaCI from 0 to 0. l 
M developed over 50 rain. I domain was then eluted with a 2 CV linear 
salt gradient run from 0.1 1.0 M NaC1 in the presence of 50 mM 
sodium phosphate, pH 6.5. Column fractions were collected and ana- 
lyzed by 10 20% SDS-PAGE; I domain was observed as a single band 
at approximately 25 kDa (Fig. 3). Purified I domain was concentrated 
to 20 mg/ml using an Amicon stirred-cell ultrafiltration module con- 
taining a YM05 membrane. The same purification procedure was used 
for metabolically abeled [tSN]I domain. 
2•2• Electrospray ionization mass spectrometry 
All electrospray ionization mass spectra (ESIMS) were recorded on 
the Vestec 201A mass spectrometer. Aliquots (0.05~).5 ¢tg) of a solution 
of the I domain in 50% acetonitrile/50% water/0.1%TFA were injected 
via a loop injector into the ion source. The mass spectrometer was 
scanned from m/z 500 to 2000 at 2 s/scan. The data were acquired with 
the Teknivent Vector 2 data system. Ten scans were averaged and 
transferred to the Harris 800 computer for further processing. The 
average molecular weights (av. MW) were determined using the cen- 
troid and deconvolution programs. 
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Fig. I. A schematic diagram of the leukocyte integrin Mac-1 f12 a- 
subunit (CD11b) with the amino acid sequence of the GST/I domain 
fusion protein. (A) The I domain resides in the N-terminal region of all 
leukocyte integrins. The signal sequence, transmembrane, and cytoplas- 
mic domains are denoted as SS, TM, and CYT, respectively. (B) The 
GST/I domain fusion construct consists of 435 amino acids. The N- 
terminal 218 amino acids comprise GST, followed by a 12 amino acid 
linker region (bold) designed to allow easy access of factor X ~, and then 
the 205 residue I domain (Ser~33-Glu337). The iI denotes the specific 
cleavage site for factor X", leaving the I domain with a 5 amino acid 
N-terminal extension. 
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Fig. 2. Purification of I domain by ion exchange chromatography• 
Factor X" digested GST/I domain was loaded directly onto a column 
of S-Sepharose Fast Flow. Chromatographic conditions were opti- 
mized to allow for complete isolation of the I domain. The relatively 
low absorbance of the I domain (as compared to the liberated GST in 
the column flowthrough) is due primarily to the absence of tryptophan 
residues. 
2.3. NMR spectroscopy 
Samples for NMR analysis contained 0.8 mM I domain, 150 mM 
NaCI and 50 mM phosphate buffer at pH 6.2. The total volume was 
440 ¢tl (400 ,ul IH20 and 40 ,ul 2H20 ). NMR spectra were recorded at 
27°C on a Bruker AMX-600 spectrometer. In all experiments, continu- 
ous wave low-power saturation was used during the relaxation delay 
to attenuate the intensity of the 'H_,O resonance. For experiments on 
[tSN]I domain, GARP decoupling [23] was used during the acquisition 
period to decouple 15N. Proton chemical shifts were referenced to the 
~H20 signal at 4.76 ppm. Nitrogen chemical shifts were referenced to 
external 2.9 M 15NH4CI in 1 M HCI at 24.93 ppm relative to liquid 
ammonia. Data were processed on a Silicon Graphics Iris Crimson 
workstation using the software package FELIX from Hare Research 
Inc. 
The two-dimensional 'H-15N HSQC spectrum [24] was acquired 
using IH and ~SN sweep widths of 9,090 Hz and 1,785 Hz, respectively. 
For each of 128 complex t~ values, 128 transients were recorded. Quad- 
rature in t~ was accomplished using the method of States et al. [25]. 
2.4. Circular dichro&m measurements 
The CD spectrum of 1 domain was measured between 20 and 22 ° C 
on a Jasco Model J-720 CD spectropolarimeter from 260 to 190 nm in 
a 0.086 mm cell. Spectra are an average of 16 scans with baseline 
subtraction. The spectrophotometer was calibrated at 290 nm with 
d-10-camphorsulfonic acid [26]. The concentration of the protein was 
42 ¢tM, 8 mM NaCI and 3 mM phosphate buffer at pH 6.5, in the 
absence or presence of 10 mM CaC12 or 10 mM MgCI~. Addition of 
calcium to the protein formed a turbid solution which was clarified by 
centrifugation. 
Molar intensities were computed from the given concentration and 
mean residue molecular weight of 113.2 g/mol. The secondary structure 
was calculated using the method of Compton and Johnson [27] and 
their data base of 16 proteins. This calculation determines the percent- 
age of the five secondary structures: a-helix, anti-parallel fl-sheet, par- 
allel fl-sheet, fl-turn, and other (random). An acceptable analysis con- 
tains no large negative values and a total secondary structure percent- 
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age of approximately 100%. The 'variable selection method' of Mana- 
valan and Johnson [28] was also applied, which allows for a decrease 
in the number of variables by removal of proteins with CD contribu- 
tions absent in the protein being analyzed, until an acceptable percent- 
age is obtained. 
3. Results and discussion 
The E. coli expression system with plasmid pG-3x-CDI lb 
provides reasonable levels of GST/I domain fusion protein. 
Purification of the GST/I domain construct over immobilized 
GSH proved to be very straightforward; good yields were ob- 
served with very high purities. In fact, the only contaminant 
observed upon SDS-PAGE analysis was a low level (< 5%) of 
free-GST, which would be expected to co-purify with the fusion 
protein. N-Terminal sequence analysis of the fusion protein 
pool yielded a single sequence corresponding to the N-terminus 
of GST. The absence of secondary sequences was good evi- 
dence that there was little or no proteolytic degradation of the 
fusion protein occurring during the initial purification step. 
Liberation of the I domain from its fusion partner was 
achieved enzymatically via incubation with factor X ". Factor 
X ~' is a serine protease which, by design of the construct, should 
specifically cleave the fusion protein at the Arg-Gly bond lead- 
ing into N-terminal extension of the I domain (Fig. 1). Factor 
X" was added directly to the purified fusion protein to a final 
concentration of 0.5% (by weight), and incubation was carried 
out at room temperature for 16-24 h. SDS-PAGE provided a 
useful technique for monitoring the completeness of digestion 
(Fig. 3, lane 3.4). 
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Fig. 3. Coomassie blue stain of a l0 20% SDS-PAGE gel monitoring 
the purification of recombinant CD1 lb I domain. Lane 1 = molecular 
weight markers x 10~; lane 2 = the E. colt lysate containing the GST/I 
domain: lane 3 = purified GST/I domain; lane 4 = Factor X" digestion 
of GST/I domain; lane 5 = purified l domain (S-Sepharose pool). 
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Fig. 4. Amino acid compositional nalysis of purified I domain. 
I domain preparations were hydrolyzed with 6 N HC1 for 22 h in vacuo 
at 110°C prior to analysis. Individual amino acid results (ordinate) were 
plotted against he theoretical composition of I domain (abscissa). 
Least squares calculation yielded a correlation of 0.994. 
Due to the charge disparity between GST (pl 6.5), factor X ~' 
(pl 7.5), and I domain (pl 9.0), ion exchange chromatography 
was selected as the final purification step. The digestion mixture 
was loaded directly onto a column of S-Sepharose Fast Flow 
under conditions which would allow the GST to flow through 
unretarded. The elution profile is shown in Fig. 2, where the 
I domain elutes as a single, homogeneous peak. In fact, the 
elution of the I domain at around 150 mM NaCI in the gradient 
results in its recovery in a physiologic-type buffer. The rela- 
tively low absorbance at 280 nm of the I domain can be ex- 
plained by its lack of tryptophan residues (e2s~ = 0.235 
1. tool - t  cm ~). Further processing of the purified 1 domain was 
limited to conventional dialysis or ultrafiltration to concentrate 
the protein to desired levels. No differences in expression levels 
or purification were seen with unlabeled versus >N-labeled l 
domain. Typically, cells harvested from 4 liters of fermentation 
generated 40 mg of final I domain product. 
Analytical characterization f the purified 1 domain revealed 
that the protein was consistently of very high purily and integ- 
rity. N-Terminal sequence analysis confirmed the presence of 
a single species exactly matching the primary structure of the 
I domain. The absence of secondary sequences was also evi- 
dence that the I domain was not significantly proteolyzed ur- 
ing its purification. This evidence is supported by the single 
species seen on SDS-PAGE at the expected molecular weight 
(Fig. 3, lane 4), as well as the data generated by amino acid 
compositional nalysis which reveals a very high correlation to 
the theoretical, full-length I domain (r: = 0.99: Fig. 4). Electro- 
spray ionization mass spectrometry was used to further define 
the 1 domain in terms of its protein chemistry. Average molec- 
ular weights of 23,769 and 24.036 daltons were obtained for 
unlabeled and ~YN-labeled 1 domain, respectfully, which are 
within one mass unit of the theoretical masses. Combined, these 
results how that the 1 domain is intact at the N- and C-termini, 
and is essentially free of post-translational modifications (ace- 
tylation, deamidation) which could alter the structural and/or 
functional integrity of this protein. 
The conformational properties of purified Mac-I ~ subunit 
I domain were studied by both CD and NMR spectroscopy. 
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Fig. 5 shows the one-dimensional 1H NMR spectrum of the 
I domain. The general resonance dispersion observed, is indica- 
tive of folded structure. The isolated methyl resonances athigh 
field (denoted by asterisks) are ring-current shifted more than 
a ppm from their normal position, indicating that they are 
situated near an aromatic ring system. This type of interaction 
is not observed in denatured or random coil proteins, and is 
thus very indicative of a folded protein. In fact, high-field reso- 
nances uch as these are excellent markers of protein integrity. 
If the I domain were to denature with time, temperature, vari- 
ation in solvent or any other condition, a change in the posi- 
tions of these resonances would be observed. Other distinct 
features of the one-dimensional spectrum include the observa- 
tion of several IH~ resonances with fl-sheet-like chemical shifts 
between 5.0 and 6.0 ppm, and the spread of IHN resonances 
from 8.0 to 10.0 ppm. 
Addition of CaC12 to the I domain solution did not produce 
obvious changes in the resulting NMR spectra, suggesting the 
sequestered I omain may not bind calcium or the cation bind- 
ing-site is occupied. In addition, NMR spectra in the presence 
of 15 mM CHAPS detergent were identical to those without 
detergent, evidence that the I domain does not aggregate at 
concentrations u ed for NMR studies. 
The CD spectra of the Mac-1 a subunit I domain in the 
absence and presence of Ca 2+ and Mg 2÷ is shown in Fig. 6. 
Scans were terminated at190 nm due to the high salt concentra- 
tion. The addition of divalent cations yielded no significant 
conformational change. The secondary structure calculations 
suggest approximately 45% of the protein is a-helix, 7% fl-sheet, 
23% fl-turn, and 25% other or random in composition. 
Extraction of detailed structural information using NMR 
spectroscopy of proteins this size requires isotopic 13C and/or 
15N enrichment [29]. Isotopic labeling increases the likelihood 
of assigning the majority of the resonances and concomitantly 
increases the number of structural constraints hat can be deter- 
mined. Fig. 7 displays the two-dimensional ~H-~SN HSQC spec- 
trum of the [JSN]I domain. Many well-dispersed correlations 
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Fig. 6. The CD spectrum of 42/IM CDllb I domain in the absence 
(solid line) and presence of l0 mM CaCl2 (solid line/cross) or l0 mM 
MgCI 2 (dash line), 8 mM NaCl, 3 mM phosphate buffer, pH 6.5. 
are observed, which is again indicative of a folded protein. It 
is apparent that the correlations documented in Fig. 7 manifest 
a range of intensities and/or line-widths. This signifies differ- 
ences in mobility across the structure of the I domain, con- 
sistent with the view that some regions exist in a more stable 
folded structure than others. 
In summary, the CD results and preliminary NMR studies 
show the Mac-1 a subunit I domain acquires a folded confor- 
mation in solution. Both CD and NMR evidence suggests that 
the majority of the I domain secondary structure isc~-helical in
nature. Furthermore, the NMR spectra suggest that I domain 
exits as a monomer and does not aggregate in solution. Al- 
though previous reports have shown the presence of a novel 
divalent cation-binding site within the I domain that is required 
for metal-dependent ligand binding [19,22,30], gross conforma- 
tional changes were not observed upon addition of Ca 2+ or 
Mg 2+ to 1 domain, possibly signifying the site is occupied. 
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Fig. 5. The 600 MHz IH NMR spectrum of 0.8 mM CDllb I domain 
in 90% ~HzO/10% 2H20, 150 mM NaC1, 50 mM phosphate buffer, pH 
6.2. The large out-of-phase r sonance at4.76 ppm arises from the water 
protons. Peaks designated with an asterisk are ring-current shifted from 
their normal position. 
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Fig. 7. Region of the 14.2 T ~H ~SN HSQC spectrum of uniformly 
15N-enriched CD1 lb I domain in 90% IH20/10% 2H20 , 150 mM NaC1, 
50 mM phosphate buffer, pH 6.2. Observed correlations arise from the 
backbone amide groups. 
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Recently il was shown that recombinant Mac-1 I domain con- 
tains an iC3b ligand binding site that is divalent cation depend- 
ent and temperature independent [31]. Sequencing of short 
strands of peptides from the I domain has determined that 
residues 330 343 (Fig. 1) bound iC3b independent of the cat- 
ion, with iC3b most likely binding to the less well conserved N- 
and C-terminus hydrophilic regions of the peptide. It was sug- 
gested that the 1 domain assumes a functionally active confor- 
mation outside the Mac-I ~ subunit [31]. Collectively, our re- 
sults from CD and NMR support he idea that I domain retains 
its functionality as an isolated subunit [13,14,18,20]. While this 
manuscript was in preparation, the crystal structure of the 
Mac-1 I domain (termed the A domain, and slightly different 
in amino acid sequence from the one described herein) was 
reported [32]. It will be of interest now to compare the solution 
structures of the I domain and I domain/ligand complexes with 
the structure determined crystallographically. 
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